Physician profile
Nicholas Licari
NPI 1558721779
$3,315.83
in general payments reported to CMS, 2019-2025
32 companies · $975 in 2025
The $975 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $396 · 2022: $507 · 2023: $802 · 2024: $636 · 2025: $975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,380 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,380.31 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $890.67 | 2021-2025 | |
| Novo Nordisk INC | $755.22 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $288.41 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $150.75 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $130.45 | 2022-2025 | |
| Amgen INC. | $127.79 | 2021-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $119.60 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.03 | 2023-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.54 | 2021-2024 | Jardiance, Synjardy, Tradjenta |
| Dexcom, INC. | $72.54 | 2023-2025 | Dexcom G6 Transmitter |
| Stryker Corporation | $60.39 | 2025 | Clottriever Bold Catheter |
| Xeris Pharmaceuticals, INC. | $59.34 | 2023 | Keveyis, Gvoke Hypopen |
| Amarin Pharma, INC. | $45.86 | 2021 | |
| Janssen Pharmaceuticals, INC | $40.27 | 2021-2022 | |
| Dynavax Technologies Corporation | $36.52 | 2023-2024 | Heplisav-B |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $34.56 | 2024-2025 | Voquezna |
| Pfizer INC. | $33.22 | 2022 | |
| Abbott Laboratories | $32.66 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals Lp | $31.25 | 2023-2024 | Airsupra |
| Merck Sharp & Dohme LLC | $28.24 | 2021 | |
| Averitas Pharma INC. | $25.11 | 2025 | Qutenza |
| Daiichi Sankyo INC. | $22.75 | 2022 | |
| Shield Therapeutics INC | $21.71 | 2023 | Accrufer |
| Sumitomo Pharma America, INC. | $20.38 | 2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $19.82 | 2025 | |
| Eisai INC. | $19.64 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.69 | 2021 | |
| Verona Pharma, INC. | $15.66 | 2025 | Ohtuvayre |
| Axsome Therapeutics, INC. | $15.21 | 2025 | Auvelity |
| Cequr Corporation | $13.89 | 2023 | Cequr Simplicity |
| Exact Sciences Corporation | $13.65 | 2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $12.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Licari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.